异基因造血干细胞移植患者巨细胞病毒感染预防与治疗的研究进展  

Progress in prevention and treatment of cytomegalovirus infection in patients with allogeneic hematopoietic stem cell transplantation

作　　者：钟书琴 李乃农[3,4] 王梅华[1,2] Zhong Shuqin;Li Nainong;Wang Meihua(Department of Clinical Laboratory,Fujian Medical University Union Hospital,Fuzhou350001,China;Laboratory Diagnostics Department,Union Clinical Medical College,Fujian Medical University,Fuzhou350001,China;Fujian Institute of Hematology,Fujian Medical University Union Hospital,Fuzhou350001,China;Translational Medicine Center on Hematology,Fujian Medical University,Fuzhou350001,China)

机构地区：[1]福建医科大学附属协和医院检验科,福州350001 [2]福建医科大学协和临床医学院实验诊断学教研室,福州350001 [3]福建医科大学附属协和医院血液科,福建省血液病研究所,福州350001 [4]福建医科大学血液病学转化医学中心,福州350001

出　　处：《中华预防医学杂志》2024年第11期1763-1770,共8页Chinese Journal of Preventive Medicine

基　　金：福建省恶性血液病临床医学研究中心(2020Y2006)。

摘　　要：异基因造血干细胞移植(allo-HSCT)仍然是血液系统恶性疾病有效的治疗手段。巨细胞病毒(CMV)感染是造血干细胞移植后常见的感染并发症之一,也是导致移植受者死亡的主要原因,对移植受者预后、生存有着重大的影响。对于感染CMV的移植患者采取及时有效的预防和治疗显得尤为重要。本文分析了移植后CMV感染的最新预防和治疗措施。通过Pubmed检索平台查找相关文献资料,就allo-HSCT患者巨细胞病毒感染的预防措施及治疗手段的新进展进行阐述。Allogeneic hematopoietic stem cell transplantation(allo-HSCT)remains an effective treatment for hematological malignancies.Cytomegalovirus(CMV)infection is one of the common Infection complications after hematopoietic stem cell transplantation,and also the main cause of death of transplant recipients,which has a significant impact on the prognosis and survival of transplant recipients.It is particularly important to take timely and effective prevention and treatment for CMV infected transplant patients.This article discusses the latest prevention and treatment of CMV infection after transplantation,and reviews the recent progress in the prevention and drug treatment of CMV infection in allo-HSCT patients by searching the relevant literature through Pubmed.

关 键 词：异基因造血干细胞移植 巨细胞病毒 感染 预防 过继性免疫细胞治疗 

分 类 号：R457.7[医药卫生—治疗学]